Porcine circovirus-associated disease (PCVAD) encompasses a variety of progressive disease syndromes that include a variety of clinical signs, such as respiratory distress, wasting, dermatitis, reduced growth performance, and reproductive failure (3, 4, 12). A new syndrome, acute pulmonary edema (APE), is characterized by the rapid onset of respiratory distress followed by death (5). Experimental studies demonstrate that the infection of pigs with porcine circovirus type 2 (PCV2) alone is necessary but not sufficient to induce PCVAD and requires additional cofactors, which can include infection with viruses or bacteria, immune stimulation following vaccination, and the genetics of the host (17, 20, 21, 27, 28, 33, 35). The contribution of cofactors in disease progression is likely related to immune modulation combined with increased numbers of proliferating lymphocytes, the primary targets of virus replication. One example is the experimental coinfection of pigs with PCV2 and porcine reproductive and respiratory syndrome virus (PRRSV). Maintenance of CP as a monomer required the presence of 20 mM 3-(cyclohexylamino)-1-propanesulfonic acid (CHAPS) to inhibit antibody recognition. Removal of a single key residue is sufficient to alter Ab recognition (42). Removal of a single key residue is sufficient to inhibit antibody recognition.

Recently, Khayat et al. (15) reported the crystal structure of PCV2 capsid protein (CP) in complex with an immunodominant epitope consisting of residues 169 to 180 [CP(169–180)], which is exposed on the surface of the subunit, but, in the structural context of the VLP, the epitope is buried and inaccessible to antibody. High levels of anti-CP(169–180) activity are associated with porcine circovirus-associated disease (PCVAD). The purpose of this study was to investigate the role of the immune response to monomer CP in the development of PCVAD. The approach was to immunize pigs with PC monomer, followed by challenge with PCV2 and porcine reproductive and respiratory syndrome virus (PRRSV). To maintain the CP immunogen as a stable monomer, CP(43–233) was fused to ubiquitin (Ub-CP). Size exclusion chromatography showed that Ub-CP was present as a single 33-kDa protein. Pigs immunized with Ub-CP developed a strong antibody response to PCV2, including antibodies against CP(169–180). However, only low levels of virus neutralizing activity were detected, and viremia levels were similar to those of nonimmunized pigs. As a positive control, immunization with baculovirus-expressed CP (Bac-CP) resulted in high levels of virus neutralizing activity, small amounts of anti-CP(169–180) activity, and the absence of viremia in pigs following virus challenge. The data support the role of CP(169–180) as an immunological decoy and illustrate the importance of the structural form of the CP immunogen in determining the outcome following infection.
the antibody response produced against the CP monomer was similar to that observed for pigs with PCVAD.

MATERIALS AND METHODS

Cloning and expression of proteins and polypeptides. A PCV2b capsid gene fragment containing amino acid residues 43 to 233 was cloned and expressed in the E. coli vector pHUE as previously described (42). To obtain enhanced green fluorescent protein (EGFP), the coding region of EGFP was PCR amplified from the pEGFP-C3 vector using the forward primer 5’-CGGCAAGCGCCGCTGGAAAGAAG and the reverse primer 5’-GAACCGCTCGGGAGAAGATTCGCGC. 

Size exclusion chromatography (SEC). A 400-ml column with 15-mm column (Fischer and Porter) was packed with Sephacryl G-200 high-resolution gel filtration medium (GE Healthcare) to a final bed volume of 60 ml. The column was equilibrated with elution buffer (EB) (50 mM NaH, PO4 300 mM NaCl, 250 mM imidazole, pH 8.0) and calibrated for a 1-ml/min flow rate, as recommended by the manufacturer. The void volume (Ve) was determined using Blue Dextran (Sigma). Proteins of known size, including bovine serum albumin (BSA; New England Biolabs), lysozyme (Sigma), and GFP fused to ubiquitin (Ub-GFP) were included as standards. Proteins and Blue Dextran were diluted in EB to a final concentration of 1 mg/ml and loaded onto the column. Two-milliliter fractions were collected. Blue Dextran was measured by absorbance at 610 nm. Protein concentrations were measured in each fraction by protein assay (Bio-Rad). The peak fraction containing Ub-GFP was confirmed by GFP fluorescence. In addition to total protein, the relative concentration of Ub-CP(43–233) was estimated by immunob assay. Briefly, from an initial dilution of 1:2, serial 2-fold dilutions of each Ub-CP(43–233) containing fraction were prepared in 0.05 M carbonate binding buffer (pH 9.6), and 100 µl of each was added to a 96-well enzyme-linked immunosorbent assay (ELISA) plate (Costar), and the plate was incubated overnight at 4°C. After incubation, plates were washed with phosphate-buffered saline (PBS) containing 0.01% Tween 20 (PBST) and blocked for 2 h at room temperature with PBS containing 10% goat serum (PBS-GS). Plate-bound antigen was detected with serum from a pig with PCVAD. Serum, diluted 1:400 in PBS plus 10% goat serum, was added to each well (Colorado Serum Company). Following incubation and washing steps, 100 µl of peroxidase-labeled goat anti-swine antibody (Accurate Chemical and Scientific Corp.), diluted 1:2,000 in PBS-GS, was added to each well. After incubation at room temperature for 1 h, plates were washed with PBST, and 100 µl of the chromogenic substrate ABTS [2,2′-azino-bis(3-ethylbenzthiazolinesulfonic acid)] (KPL) was added to each well. Peroxidase activity was detected by measuring the absorbance at 405 nm. A standard curve was constructed by plotting the elution volume (Ve) divided by V0 against the log10 of the formula weight of each standard.

Animal experiments. Experiments involving animals were performed after approval by Kansas State University Institutional Animal Use and Biosafety committees. PCV2-negative pigs were derived as described by Opreisng et al. (29). Briefly, offspring from pregnant dams possessing indirect fluorescence antibody (IFA) titers of less than 320 were selected. At 3 weeks of age, 26 pigs, confirmed PCR negative for PCV2 and with low
ogy and PCV2 immunohistochemistry (IHC).

pigs were monitored daily for clinical signs, and blood samples were col-

intranasally, with 1.5 ml divided between nares. Following virus challenge,

doses (TCID50) for each virus. The 3-ml virus inoculum was administered

to the Kansas Veterinary Diagnostic Laboratory (KSVDL). Briefly, total

TaqMan PCR assay, performed as routine diagnostic tests by personnel in

toxylin and eosin.

chromogen (Ventana Medical). Slides were counterstained with hema-

polyclonal antibody (Veterinary Medical Research and Development,

Ventana Medical). PCV2 antigen was detected using a rabbit anti-PCV2

affin-embedded sections were mounted on slides, deparaffinized, and

were immediately placed in 10% buffered formalin. After processing, par-

IHC staining on paraffin-embedded tissue sections. At necropsy, tissues

IFA titers, were assigned to three treatment groups with eight pigs in each
group, plus a reference control group of two pigs. The seven pigs that
possessed maternally derived antibodies were divided equally between
treatment groups. Table 1 and Fig. 2 show the experimental groups and
the timeline for the experiment, respectively. Treatment groups included
pigs immunized with Ub-CP, pigs immunized with Bac-CP (commercial
vaccine), and pigs that were not immunized (nonimmunized, or non-
IM). The reference control group contained two pigs that were neither
immunized nor challenged. The Ub-CP immunogen consisted of Ub-
CP(43-233) at a concentration of 50 μg/ml emulsified in Emulsigen-D
adjuvant (20%, vol/vol; MVP Technologies), gentamicin (30 μg/ml), and
thimerosal (0.01%) prepared in a 2-ml volume of minimal essential me-
edium (MEM). Pigs were immunized intramuscularly with a 2-ml dose at
4 and 7 weeks of age. The Bac-CP immunogen consisted of a commercial
countervaccine (Intervet-Schering Plough) administered as a 2-ml dose at 4 and 7
weeks of age, according to the label instructions. The PCV2b-PRRSV
preparation used for challenge was the same as described previously (42,
43). Pigs in each treatment group were intermingled and challenged with
PCV2b-PRRSV at a dose of approximately 10⁵ 50% tissue culture infective
doses (TCID₅₀) for each virus. The 3-ml virus inoculum was administered
intranasally, with 1.5 ml divided between nares. Following virus challenge,
pigs were monitored daily for clinical signs, and blood samples were col-
lected weekly. Weights were measured at the beginning of the study, at
virus challenge, and at the termination of the study. At the end of the
study, lung, kidney, and lymphoid tissues were collected for histopathol-
ogy and PCV2 immunohistochemistry (IHC).

Immunohistochemistry for PCV2. PCV2 antigen was detected by IHC
staining on paraffin-embedded tissue sections. At necropsy, tissues
were immediately placed in 10% buffered formalin. After processing, par-
affin-embedded sections were mounted on slides, deparaffinized, and
stained using an automated procedure (NexES IHC Staining Module;
Ventana Medical). PCV2 antigen was detected using a rabbit anti-PCV2
polyclonal antibody (Veterinary Medical Research and Development,
Inc.) Bound antibody was detected with biotinylated goat anti-rabbit IgG
followed by avidin-horseradish peroxidase and diaminobenzidine (DAB)
chromogen (Ventana Medical). Slides were counterstained with hema-
toxylin and eosin.

PCV2 PCR. PCV2 in serum was measured using a semiquantitative
TaqMan PCR assay, performed as routine diagnostic tests by personnel in
the Kansas Veterinary Diagnostic Laboratory (KSVDL). Briefly, total
DNA was isolated from serum using a MagMAX-96 Viral DNA Isolation
Kit (Applied Biosystems) according to the manufacturer’s instructions.
The PCRs were carried out on a QST 7500 Real-Time PCR System (Ap-
plied Biosystems) in a 96-well format. For the construction of a standard
curve, dilutions of template DNA were prepared and assayed concurrently
with the samples. The assay results were reported as the log₁₀ of PCV2
DNA copy number per 50-μl reaction volume.

Measurements of PCV2 and PRRSV antibodies. Total PCV2 anti-
body in serum was measured by IFA as previously described (43). Briefly,
rapidly dividing swine testicle (ST) cells, maintained in MEM with 7%
fetal bovine serum (FBS) and gentamicin (30 μg/ml MEM-FBS-Gent) on
96-well plates, were infected with a laboratory isolate of PCV2b. Three
days later, the plates were fixed in 80% acetone. Serum samples were
added at an initial dilution of 1:40 followed by serial 1:2 dilutions in a total
volume of 100 μl. Samples were diluted in PBS with 10% fetal bovine
serum (PBS-FBS, Sigma) and incubated for 2 h at room temperature.
After samples were washed with PBS, fluorescein isothiocyanate (FITC)-
labeled anti-pig antibody (Jackson Laboratory) diluted 1:2,000 in PBS-
FBS was added to each well. Plates were incubated for 2 h at room tem-
perature, washed, and viewed on an inverted fluorescence microscope.
The results were reported as the reciprocal of the last serum dilution
diluting fluorescence.

PCV2 neutralizing activity was measured as previously described (43).
Briefly, serial 1:2 dilutions of serum were prepared in MEM-FBS-Gent.
Four 100-μl replicates of each dilution were mixed with 100 TCID₅₀ of
PCV2b (100 μl each) and incubated for 1 h at 37°C. WS the well contents
were transferred onto day-old ST cells in 96-well plates. Following incu-
bation for 4 days at 37°C, wells were fixed in 80% acetone. Infection was
detected with anti-PCV2 antibody (kindly provided by Ying Fang), di-
luted 1:2,000 in phosphate-buffered saline (PBS), followed by incubation
with FITC-labeled anti-mouse antibody (Jackson Laboratory). The log₂
50% neutralizing antibody (NA₅₀) endpoint was calculated according to
the method of Spearman and Karber (9).

Anti-CP(169-180) antibody was measured by ELISA on 96-well plates
coated with 100 μl of CP(169-180) oligopeptide (21st Century Biochem-
icals) at a concentration of 4 μg/ml (42, 43). Plates were incubated over-
night at 4°C. After being washed with PBS containing 0.05% Tween 20
(PBST), plates were blocked for 2 h at room temperature (RT) with PBS
containing 10% fetal bovine serum (PBS-FBS). Serum, diluted 1:400 in PBS-FBS,
was added to each well and incubated for 2 h at RT. Plates were washed
with PBST, and 100 μl of peroxidase-labeled goat anti-swine antibody
(Accurate Chemical and Scientific Corp.), diluted 1:2,000 in PBS-GS, was
added to each well. After incubation at RT for 1 h, plates were washed
with PBST, and 100 μl of ABTS was added to each well. Peroxidase activity
was detected by measuring the absorbance at 405 nm on a FLUOstar Omega
instrument (BMG Labtech). To compare results across experiments, each
ELISA plate included an internal positive control as previously described
(42, 43). Results were reported as the antibody binding ratio, calculated as
the A₄₀₅ value of the unknown sample minus background divided by the
A₄₀₅ value of the internal positive control minus background.

PRRSV-specific antibody was analyzed by a commercially available
ELISA (PRRS X3; IDEXX). Samples were considered positive if the ratio of

TABLE 1 Treatment groups

<table>
<thead>
<tr>
<th>Group (n)</th>
<th>Immunogen</th>
<th>PCV2/PRRSV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-IM (8)</td>
<td>None</td>
<td>Yes</td>
</tr>
<tr>
<td>Bac-CP (8)</td>
<td>Bac-CP vaccine</td>
<td>Yes</td>
</tr>
<tr>
<td>Ub-CP (8)</td>
<td>Ub-CP</td>
<td>Yes</td>
</tr>
<tr>
<td>Control (2)</td>
<td>None</td>
<td>No</td>
</tr>
</tbody>
</table>

a n, number of pigs.
the sample to the positive control was greater than 0.39, as recommended by the manufacturer.

**Statistical methods.** Statistical analysis was performed using GraphPad Prism, version 5.04, for Windows (GraphPad Software, San Diego, CA). Data incorporating repeated measures were analyzed by one-way analysis of variance followed by a Tukey posttest. Differences at specific time points were analyzed by a Kruskal-Wallis test. If significant differences were detected, specific groups at time points were assessed using Wilcoxon’s test. Nonrepeated measures were analyzed using a Kruskal-Wallis test. If differences were identified, measures were further assessed by Wilcoxon’s test.

**RESULTS**

**SEC of Ub-CP(43–233).** In this study, a 76-amino-acid ubiquitin molecule was fused to CP(43–233) as a means to maintain CP in a stable monomeric form. The removal of ubiquitin with the deubiquitylating enzyme, Usp-2cc (2), resulted in precipitation of CP(43–233) (data not shown). The expressed fusion protein was analyzed by SDS-PAGE. As shown in Fig. 3A, purified Ub-CP was present as a single 33-kDa protein, which is similar to the formula weight calculated for the 6 × His-Ub-CP fusion protein. The structural form of Ub-CP was analyzed by size exclusion chromatography (SEC) on Sephacryl G-200. Monograms for total protein and immunoreactive Ub-CP are shown in Fig. 3B. Total and immunoreactive protein monograms were similar. Immunoreactive CP showed minor peaks in fractions 14, 17, and 20, which suggested the presence of a small quantity of Ub-CP in multimeric forms. Plotting the major peak against the standard curve showed that Ub-CP eluted as a 34.3-kDa molecule. Based on these results, the Ub-CP used for the immunization of pigs was present as a relatively pure monomer protein with only a small amount of Ub-CP present in a multimeric form.

**Clinical disease and outcome.** The overall design of the experiment is shown in Fig. 2. At approximately 7 days after virus challenge, pigs in all virus groups showed signs of mild respiratory distress, a clinical sign associated with acute porcine reproductive and respiratory syndrome (PRRS). The two pigs in the nonchallenged control group remained healthy. Serology confirmed that all virus-challenged pigs were positive for PRRSV (data not shown). At the end of the study, histopathology showed lesions in the lungs, including interstitial pneumonia with the infiltration of lymphocytes, macrophages, and neutrophils. IHC showed PCV2 antigen in lung tissue sections from all infected groups. PCV2 staining was localized in the bronchial epithelium. However, there was a difference in the number of pigs with antigen staining in lung. The greatest number of pigs positive for PCV2 antigen was in the Ub-CP group (six of eight pigs positive for PCV2 antigen), followed by the nonimmunized group (four of eight pigs), and the Bac-CP group (two of eight pigs).

**Antibody response to PCV2.** Serum samples, collected before and after immunization, were tested for total PCV2 antibody by IFA (Fig. 4). At the beginning of the study, low levels of PCV2-specific antibodies were detected in several pigs, likely the result of maternally derived antibody. For the Ub-CP group, a detectable increase in mean Ab titer was observed at the time of the second immunization (day −14), which peaked at the time of virus challenge and was followed by a second peak 28 days after challenge. Pigs immunized with the PCV2 vaccine, Bac-CP, showed a statistically similar antibody response. For the non-IM group, antibody was detected by 21 days after virus challenge and peaked by 28 days. For days 21 to 42 after infection, the IFA titers for the three challenge groups were similar and not statistically different. PCV2 antibody titers for the two nonchallenged control pigs remained below detectable levels throughout the study.

Serum samples were also reacted with the CP(169–180) oligopeptide. Significant amounts of anti-CP(169–180) binding activity were detected in the group Ub-CP pigs at the time of virus challenge and remained elevated throughout the remainder of the study period (Fig. 4B). In contrast, anti-CP(169–180) activity in the Bac-CP group remained near background levels and similar to the levels for the two noninfected control pigs. Following virus challenge, the non-IM group showed anti-CP(169–180) activity, which first appeared at 21 days after infection and peaked at the same level of binding activity as that of the Ub-CP group.

Results for PCV2 neutralizing activity for day −35 (time of first immunization), day 0 (time of virus challenge), 7 days after challenge, and at the termination of the study are presented in Fig. 5. At day −35, small amounts of neutralizing activity were detected, a likely result of maternal antibody present in the serum. After two immunizations with baculovirus-expressed CP, neutralizing activity was significantly higher than in the non-IM and Ub-CP groups. The level of neutralizing activity for the Bac-CP group remained significantly elevated throughout the remainder of the study period.
The decrease in the levels of neutralizing activity in the non-IM and Ub-CP groups likely reflects the gradual decay of maternal antibody.

**PCV2 viremia.** All pigs were negative for PRRSV and PCV2 by PCR at the beginning of the study. PCV2 DNA was first detected at 14 days after virus challenge in the Ub-CP and Non-Im groups (Fig. 6). Mean viremia levels for the two groups were similar, with no significant differences between groups on any day after infection. Viremia in the Bac-CP group remained below detectable levels throughout the study. After virus challenge, pigs from all three treatment groups were intermingled. Even though the Bac-CP group remained constantly exposed to viremic pigs, all pigs in the Bac-CP group remained negative for the presence of PCV2 DNA in serum.

**DISCUSSION**

Previous work showed that the antibody in pigs with PCVAD is primarily directed toward an immunodominant oligopeptide epitope, CP(169–180), located within the epitope C region of CP (42). In this study, the antibody response of PCVAD pigs was mimicked by immunizing pigs with a monomer form of CP. The outcomes following immunization with monomer CP included high levels of anti-PCV2 antibody, antibody recognition of CP(169–180), undetectable levels of virus neutralizing activity, and the absence of protection following virus challenge. Since baculovirus- and E. coli-expressed CP spontaneously form VLPs, one of the first obstacles was to maintain the CP immunogen in a stable monomeric form. This was achieved by the fusion of CP to ubiquitin to form Ub-CP. In a similar manner, Yin et al. (46) incorporated SUMO for the expression of single CP subunits. Similar to the cleavage of Ub from Ub-CP, the removal of SUMO with the SUMO protease resulted in the spontaneous assembly of CP into VLPs. How fusion with Ub or SUMO functions to prevent VLP formation is not clear. One possibility is that the fusion partner sterically blocks the interaction between CP subunits. Another possibility is that the addition of Ub or SUMO prevents subunit association through a conformational change in the CP monomer. Regardless of the mechanism for blocking VLP formation, the immunization of pigs with Ub-CP resulted in the production of antibodies against CP(169–180). As a positive control for these experiments, pigs were immunized with a commercial baculovirus-expressed CP vaccine. For the Bac-CP group, the total PCV2 antibody response followed a course similar to that of pigs immunized with Ub-CP (Fig. 4A). In contrast, the Bac-CP-vaccinated pigs possessed high levels of virus neutralizing activity and low levels of anti-CP(169–180) activity and showed no evidence of viremia after virus challenge.

In this study, the infection of pigs with a combination PCV2 and PRRSV did not result in mortality or the appearance of full-blown PCVAD, which was observed previously (1, 30, 36, 40, 43).
It is difficult to faithfully reproduce PCVAD, even in the presence of known infectious disease cofactors. The absence of PCVAD in this study is likely the result of other, yet unknown factors that are involved in disease progression. The initial high health status of the pigs and high level of care may slow down disease progression and/or suppress clinical signs. Another possibility is that the experiment was terminated before PCVAD could develop. As shown in Fig. 6, virus was still present in sera of group Ub-CP and non-IM pigs. Continued virus replication may have eventually culminated in disease.

A potential role for anti-CP(169–180) antibodies in the development of PCVAD was evident by the number of pigs with antigen in the lung. For the non-IM and Bac-CP groups, four of eight and two of eight pigs, respectively, were positive for antigen staining in the lungs. In contrast, six of eight pigs in the Ub-CP group showed antigen staining in the lung. In all cases, PCV2 virus was localized in the bronchiolar epithelium. In PCVAD cases, the lung is one of the primary targets for PCV2 infection. For example, the APE syndrome is associated with massive quantities of PCV2 replication in the lung, which results in pulmonary edema (5). PCV2 antigen in lung is associated with the onset of porcine respiratory disease complex (3, 31). Further, Shen et al. (38) showed that PCV2 DNA was more prevalent in the lung than in the serum of pigs with PCVAD. One interesting observation in this study was the presence of PCV2 antigen in the lung epithelium of the pigs in the Bac-CP group, even in the absence of viremia. These results suggest that the lung represents a site for continuous shedding of virus, even in vaccinated populations.

The most intriguing feature of PCV2 infection is the dysregulation of the immune response, which culminates in a variety of disease outcomes. On one extreme is porcine multisystemic wasting syndrome (PMWS) which, in the end stage of the disease process, results in an almost complete elimination of B and T cells and the eventual decay of anti-PCV2 antibody (4). On the other extreme, porcine dermatitis and nephropathy syndrome (PDNS) is characterized by hyperimmunoreactivity, including immune complex formation and deposition of antigen–antibody complexes in organs, such as kidney and skin (3). We propose that antibody recognition of CP(169-180) functions similar to an immunological decoy, which directs the humoral response away from protective epitopes. The decoy antibody response is the result of host recognition of CP monomer or fragments produced during virus replication. Classic examples of immunological decoys are found in lentiviruses, such as feline immunodeficiency virus (FIV) and human immunodeficiency virus (HIV). As reviewed by Hosie et al. (13), the variable regions V3, V4, and V5 of the envelope (Env) protein of FIV are essential for virus infection, are immunodominant, and are targets for neutralization by antibody. However, continuous variation, as a result of shortening, lengthening, and/or peptide sequence hypervariability, produces large quantities of antibodies that are nonprotective. A similar mechanism occurs in the HIV glycoprotein 120 (gp120) (41). PRRSV possesses a hypervariable region in GP5 that may function in a similar manner by continually recruiting B cells that do not produce neutralizing antibody (32). An example of a nonessential protein functioning as a decoy is proposed for gp150 of gammaherpesvirus 68. The protein is immunodominant and results in a nonprotective antibody response (11). In sharp contrast to lentiviruses, PCV2 possesses a rather small genome dominated by two relatively conserved proteins. Furthermore, CP is essential for virion integrity, infection, and replication. Therefore, when a decoy strategy is employed, the virus does not possess the luxury of peptide sequence hypervariability or the production of a nonessential protein. As illustrated in the model, presented in Fig. 7, we propose that PCV2 incorporates a unique strategy for employing a decoy epitope as a defense mechanism. Under normal circumstances, the immune response following PCV2 infection favors the production of antibodies directed against the whole virion. The resulting outcome is the control of virus replication and the generation of protective immunity. In contrast, the recognition of free CP and CP fragments, produced by infected cells, results in the production of antibodies against CP(169-180). Co-factors, such as coinfecting pathogens, may increase PCV2 replication and as a result may increase the level of non-VLP forms of CP. Recognition of CP(169-180) results in the production of non-protective antibodies, thus allowing for increased PCV2 replication and the progression toward disease. Host genetics or coinfections may further modulate the host response, favoring the recognition CP(169-180). This model explains why the amount of circulating antibody fails to correlate with the outcome following PCV2 infection and provides important considerations in the design of PCV2 vaccines.

ACKNOWLEDGMENTS

This work was supported by National Pork Board grant 06-073 and USDA NR1 grant 2009-35204-05290. Images of the PCV2 CP subunit and VLP were reproduced using the UCSF Chimera package from the Resource for Biocomputing, Visualization and Informatics at the University of California, San Francisco (supported by NIH P41 RR001081) (34).

We especially thank Ying Fang for the anti-PCV2 antibody.

REFERENCES


17. Reference deleted.


